Pharmacokinetics and Dialytic Clearance of Isavuconazole during In Vitro and In Vivo Continuous Renal Replacement Therapy
| Autor: | Eric Wenzler, Mark Biagi, Shitalben R. Patel, David A Butler, Samah Qasmieh, Minh Hong Nguyen, Ryan K. Shields, Xing Tan, Ryan M. Rivosecchi, Cornelius J. Clancy, K Tejani |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pharmacology
0303 health sciences 030306 microbiology business.industry medicine.medical_treatment Renal function Clinical Therapeutics In vitro 03 medical and health sciences 0302 clinical medicine Infectious Diseases Blood serum Pharmacokinetics In vivo Pharmacodynamics Blood plasma Medicine Pharmacology (medical) 030212 general & internal medicine Renal replacement therapy business |
| Zdroj: | Antimicrob Agents Chemother |
| ISSN: | 1098-6596 0066-4804 |
| Popis: | The pharmacokinetics (PK) and dialytic clearance of isavuconazole in vitro and in 7 solid-organ transplant patients undergoing continuous renal replacement therapy (CRRT) were evaluated. In vivo, the mean (± standard deviation [SD]) plasma PK parameters of isavuconazole were as follows: maximum concentration of drug in serum (C(max)), 4.00 ± 1.45 mg/liter; minimum concentration of drug in serum (C(min)), 1.76 ± 0.76 mg/liter; half-life (t(1/2)), 48.36 ± 29.78 h; volume of distribution at steady state (V(ss)), 288.78 ± 182.11 liters, clearance at steady state (CL(ss)), 4.85 ± 3.79 liters/h; and area under the concentration-time curve (AUC), 54.01 ± 20.98 mg · h/liter. Transmembrane clearance represented just 0.7% of the total isavuconazole clearance. These data suggest that isavuconazole is not readily removed by CRRT and no dose adjustments are necessary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|